Document Server@UHasselt >
Research publications >
Please use this identifier to cite or link to this item:
|Title: ||Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study|
|Authors: ||Vosse, D.|
van der Heijde, D.
van der Linden, S.
van Staa, T-P
|Issue Date: ||2009|
|Publisher: ||B M J PUBLISHING GROUP|
|Citation: ||ANNALS OF THE RHEUMATIC DISEASES, 68(12). p. 1839-1842|
|Abstract: ||Background and aims: Ankylosing spondylitis (AS) is associated with bone loss in the vertebrae and an increased prevalence of vertebral fractures, but literature about the magnitude of the risk of fracturing is limited. One retrospective cohort study provided evidence of an increased risk of clinical vertebral fractures but not of non-vertebral fractures. This study further explores the risk of clinical vertebral and non-vertebral fractures in a large population database. Methods: In a primary care-based nested case-control study, 231 778 patients with fracture and 231 778 age-and sex-matched controls were recruited. A history of AS was assessed from the medical records. Odds ratios (OR) and 95% confidence intervals (CI) were calculated after adjustment for medication, other illnesses, smoking and body mass index when known. Results: AS was diagnosed in 758 subjects. The prevalence of AS was 0.18% in patients with fracture and 0.15% in controls. Patients with AS had an increased risk of clinical vertebral fracture (OR 3.26; 95% CI 1.51 to 7.02). The risk of fractures of the forearm and hip was not significantly increased (OR 1.21; 95% CI 0.87 to 1.69 and OR 0.77; 95% CI 0.43 to 1.37, respectively). The risk of any clinical fracture was increased in patients with AS with a history of inflammatory bowel disease (OR 2.79; 95% CI 1.10 to 7.08), whereas it was decreased in patients with AS taking non-steroidal anti-inflammatory drugs (OR 0.65; 95% CI 0.50 to 0.84). The risk was not associated with recent back pain, psoriasis, joint replacement therapy and use of sulfasalazine. Conclusions: Patients with AS have an increased risk of clinical vertebral fracture but not of non-vertebral fractures, while the risk of any clinical fracture is increased in patients with concomitant inflammatory bowel disease. The mechanism by which non-steroidal anti-inflammatory drugs reduce the risk of any clinical fracture warrants further research.|
|Notes: ||[Vosse, D.; Landewe, R.; van der Heijde, D.; van der Linden, S.; Geusens, P.] Univ Hosp Maastricht, Dept Internal Med, Div Rheumatol, NL-6202 AZ Maastricht, Netherlands. [Geusens, P.] Limburgs Univ Centrum, Dept Rheumatol, Diepenbeek, Belgium. [van Staa, T-P] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Utrecht, Netherlands. [van Staa, T-P] Univ Southampton, MRC, Epidemiol Resource Ctr, Southampton Gen Hosp, Southampton, Hants, England. [van Staa, T-P] Univ Southampton, Southampton Gen Hosp, Ctr Dev Origins Hlth & Adult Dis, Southampton, Hants, England.|
|ISI #: ||000271730700008|
|Type: ||Journal Contribution|
|Validation: ||ecoom, 2010|
|Appears in Collections: ||Research publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.